Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Advanced Malignancies × Everolimus × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 13 Carcinoma, Renal Cell 6 Tuberous Sclerosis 5 Neoplasm Metastasis 5 Hodgkin Disease 5 Glioblastoma 5 Colorectal Neoplasms 5 Central Nervous System Neoplasms 5 Waldenstrom Macroglobulinemia 4 Stomach Neoplasms 4 Precursor Cell Lymphoblastic Leukemia-Lymphoma 4 Pancreatic Neoplasms 4 Lymphoma, Mantle-Cell 4 Head and Neck Neoplasms 4 Gliosarcoma 4 Triple Negative Breast Neoplasms 3 Squamous Cell Carcinoma of Head and Neck 3 Sezary Syndrome 3 Recurrence 3 Prostatic Neoplasms 3 Neoplasms 3 Mycosis Fungoides 3 Lymphoma, T-Cell, Cutaneous 3 Lymphoma, Large-Cell, Anaplastic 3 Lymphoma, Large B-Cell, Diffuse 3 Lymphoma, Follicular 3 Lymphoma, B-Cell, Marginal Zone 3 Leukemia, Lymphocytic, Chronic, B-Cell 3 Leukemia 3 Kidney Neoplasms 3

Interventions

pembrolizumab 1 liposomal doxorubicin 1 Everolimus 1 Capecitabine 1 AZD7648 1 1-dodecylpyridoxal 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01079702 2010-03-03

m-TOR

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Phase 1/2 Unknown

Advanced Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon ⚡